

Cystic Fibrosis Drugs-North America Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/C17008A41CDEN.html

Date: November 2017

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: C17008A41CDEN

Abstracts

Report Summary

Cystic Fibrosis Drugs-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cystic Fibrosis Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Cystic Fibrosis Drugs 2013-2017, and development forecast 2018-2023

Main market players of Cystic Fibrosis Drugs in North America, with company and product introduction, position in the Cystic Fibrosis Drugs market

Market status and development trend of Cystic Fibrosis Drugs by types and applications

Cost and profit status of Cystic Fibrosis Drugs, and marketing status

Market growth drivers and challenges

The report segments the North America Cystic Fibrosis Drugs market as:

North America Cystic Fibrosis Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

United States Canada Mexico

North America Cystic Fibrosis Drugs Market: Product Type Segment Analysis



(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral

Injection

North America Cystic Fibrosis Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Other

North America Cystic Fibrosis Drugs Market: Players Segment Analysis (Company and Product introduction, Cystic Fibrosis Drugs Sales Volume, Revenue, Price and Gross Margin):

Actavis

F. Hoffmann-La Roche

Gilead Sciences

Novartis

Vertex Pharmaceuticals

Abbott

Anthera Pharmaceuticals

Arcturus Therapeutics

Boehringer Ingelheim

Chiesi Farmaceutici

Corbus Pharmaceuticals

Genzyme

Insmed

Johnson & Johnson

Merck Sharp & Dohme

Neovii Biotech

Novo Nordisk

PharmaSwiss

Pharmaxis

Proteostasis Therapeutics

PTC Therapeutics



United Medical Venus Remedies

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF CYSTIC FIBROSIS DRUGS

- 1.1 Definition of Cystic Fibrosis Drugs in This Report
- 1.2 Commercial Types of Cystic Fibrosis Drugs
 - 1.2.1 Oral
 - 1.2.2 Injection
- 1.3 Downstream Application of Cystic Fibrosis Drugs
 - 1.3.1 Hospitals
- 1.3.2 Clinics
- 1.3.3 Other
- 1.4 Development History of Cystic Fibrosis Drugs
- 1.5 Market Status and Trend of Cystic Fibrosis Drugs 2013-2023
- 1.5.1 North America Cystic Fibrosis Drugs Market Status and Trend 2013-2023
- 1.5.2 Regional Cystic Fibrosis Drugs Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Cystic Fibrosis Drugs in North America 2013-2017
- 2.2 Consumption Market of Cystic Fibrosis Drugs in North America by Regions
 - 2.2.1 Consumption Volume of Cystic Fibrosis Drugs in North America by Regions
 - 2.2.2 Revenue of Cystic Fibrosis Drugs in North America by Regions
- 2.3 Market Analysis of Cystic Fibrosis Drugs in North America by Regions
 - 2.3.1 Market Analysis of Cystic Fibrosis Drugs in United States 2013-2017
 - 2.3.2 Market Analysis of Cystic Fibrosis Drugs in Canada 2013-2017
 - 2.3.3 Market Analysis of Cystic Fibrosis Drugs in Mexico 2013-2017
- 2.4 Market Development Forecast of Cystic Fibrosis Drugs in North America 2018-2023
- 2.4.1 Market Development Forecast of Cystic Fibrosis Drugs in North America 2018-2023
 - 2.4.2 Market Development Forecast of Cystic Fibrosis Drugs by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole North America Market Status by Types
 - 3.1.1 Consumption Volume of Cystic Fibrosis Drugs in North America by Types
 - 3.1.2 Revenue of Cystic Fibrosis Drugs in North America by Types
- 3.2 North America Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in United States



- 3.2.2 Market Status by Types in Canada
- 3.2.3 Market Status by Types in Mexico
- 3.3 Market Forecast of Cystic Fibrosis Drugs in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Cystic Fibrosis Drugs in North America by Downstream Industry
- 4.2 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in United States
- 4.2.2 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Canada
- 4.2.3 Demand Volume of Cystic Fibrosis Drugs by Downstream Industry in Mexico
- 4.3 Market Forecast of Cystic Fibrosis Drugs in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CYSTIC FIBROSIS DRUGS

- 5.1 North America Economy Situation and Trend Overview
- 5.2 Cystic Fibrosis Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 CYSTIC FIBROSIS DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

- 6.1 Sales Volume of Cystic Fibrosis Drugs in North America by Major Players
- 6.2 Revenue of Cystic Fibrosis Drugs in North America by Major Players
- 6.3 Basic Information of Cystic Fibrosis Drugs by Major Players
- 6.3.1 Headquarters Location and Established Time of Cystic Fibrosis Drugs Major Players
- 6.3.2 Employees and Revenue Level of Cystic Fibrosis Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 CYSTIC FIBROSIS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Actavis



- 7.1.1 Company profile
- 7.1.2 Representative Cystic Fibrosis Drugs Product
- 7.1.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Actavis
- 7.2 F. Hoffmann-La Roche
 - 7.2.1 Company profile
 - 7.2.2 Representative Cystic Fibrosis Drugs Product
 - 7.2.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-

La Roche

- 7.3 Gilead Sciences
 - 7.3.1 Company profile
 - 7.3.2 Representative Cystic Fibrosis Drugs Product
- 7.3.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Gilead Sciences
- 7.4 Novartis
 - 7.4.1 Company profile
 - 7.4.2 Representative Cystic Fibrosis Drugs Product
- 7.4.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.5 Vertex Pharmaceuticals
 - 7.5.1 Company profile
 - 7.5.2 Representative Cystic Fibrosis Drugs Product
- 7.5.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Vertex Pharmaceuticals
- 7.6 Abbott
 - 7.6.1 Company profile
 - 7.6.2 Representative Cystic Fibrosis Drugs Product
 - 7.6.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Abbott
- 7.7 Anthera Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative Cystic Fibrosis Drugs Product
- 7.7.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Anthera Pharmaceuticals
- 7.8 Arcturus Therapeutics
 - 7.8.1 Company profile
 - 7.8.2 Representative Cystic Fibrosis Drugs Product
- 7.8.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics
- 7.9 Boehringer Ingelheim
- 7.9.1 Company profile
- 7.9.2 Representative Cystic Fibrosis Drugs Product



- 7.9.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.10 Chiesi Farmaceutici
 - 7.10.1 Company profile
 - 7.10.2 Representative Cystic Fibrosis Drugs Product
- 7.10.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Chiesi Farmaceutici
- 7.11 Corbus Pharmaceuticals
 - 7.11.1 Company profile
 - 7.11.2 Representative Cystic Fibrosis Drugs Product
- 7.11.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Corbus Pharmaceuticals
- 7.12 Genzyme
 - 7.12.1 Company profile
 - 7.12.2 Representative Cystic Fibrosis Drugs Product
 - 7.12.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Genzyme
- 7.13 Insmed
 - 7.13.1 Company profile
 - 7.13.2 Representative Cystic Fibrosis Drugs Product
 - 7.13.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Insmed
- 7.14 Johnson & Johnson
 - 7.14.1 Company profile
 - 7.14.2 Representative Cystic Fibrosis Drugs Product
- 7.14.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.15 Merck Sharp & Dohme
 - 7.15.1 Company profile
 - 7.15.2 Representative Cystic Fibrosis Drugs Product
 - 7.15.3 Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin of Merck Sharp
- & Dohme
- 7.16 Neovii Biotech
- 7.17 Novo Nordisk
- 7.18 PharmaSwiss
- 7.19 Pharmaxis
- 7.20 Proteostasis Therapeutics
- 7.21 PTC Therapeutics
- 7.22 United Medical
- 7.23 Venus Remedies



CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CYSTIC FIBROSIS DRUGS

- 8.1 Industry Chain of Cystic Fibrosis Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CYSTIC FIBROSIS DRUGS

- 9.1 Cost Structure Analysis of Cystic Fibrosis Drugs
- 9.2 Raw Materials Cost Analysis of Cystic Fibrosis Drugs
- 9.3 Labor Cost Analysis of Cystic Fibrosis Drugs
- 9.4 Manufacturing Expenses Analysis of Cystic Fibrosis Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF CYSTIC FIBROSIS DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Cystic Fibrosis Drugs-North America Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/C17008A41CDEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C17008A41CDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970